This article is more than 5 years old. Information may no longer be current.
Vitiligo, psoriasis news top dermatology reads for week
Research finding that patients who underwent hematopoietic stem cell transplantation had a significantly increased rate of vitiligo development compared with controls was among the most-read articles of the past week on Healio.com/Dermatology.
Other widely read articles included the FDA’s approval of Enbrel to treat children with plaque psoriasis and findings that Xeljanz shows promise as treatment for alopecia areata in adolescents:
Vitiligo rates increase after hematopoietic stem cell transplantation
Patients who underwent hematopoietic stem cell transplantation had a significantly increased rate of vitiligo development compared with controls, according to study results published in the Journal of the American Academy of Dermatology.
Researchers used the Korean National Health Insurance Claims Database to perform a nationwide, population-based cohort study between 2009 and 2013. Read more
FDA approves Enbrel to treat children with plaque psoriasis
The FDA has approved Amgen’s supplemental biologics license application for expanded use of Enbrel for treating pediatric patients aged 4-17 years with chronic moderate-to-severe plaque psoriasis, according to a press release from the drug’s manufacturer.
“Until now, no biologics – which are effective in treating adults with moderate-to-severe plaque psoriasis – had been approved in the U.S. for the treatment of moderate-to-severe plaque psoriasis in children,” Randy Beranek, president and CEO of the National Psoriasis Foundation, stated in the release. “This new approval is an important development for this patient community, as well as their parents and families, and marks a significant milestone in advancing the treatment of children living with this devastating disease.” Read more
Xeljanz shows promise as treatment for alopecia areata in adolescents
Treatment with Xeljanz in adolescents with alopecia areata resulted in significant hair regrowth for the majority of the patients, with mild adverse events, according to recently published study results.
Brent A. King, MD, PhD, assistant professor of dermatology, Yale School of Medicine, and colleagues studied 13 adolescent patients (median age 15 years; 77% male) with alopecia areata treated with Xeljanz (tofacitinib, Pfizer) between July 2014 and May 2016 at a tertiary care center clinic. Read more
Cellceutix begins trial of oral Prurisol in treating chronic plaque psoriasis
Cellceutix Corporation has begun screening patients for a phase 2b clinical trial of oral Prurisol for treating moderate-to-severe chronic plaque psoriasis, according to a press release.
Prurisol is a novel dermatology compound in mid-stage development as an oral psoriasis treatment. Read more
Melanoma-associated leukoderma may be misdiagnosed as vitiligo
Experts frequently misdiagnosed melanoma-associated leukoderma as vitiligo in a blinded assessment, according to study results recently published in the Journal of the American Academy of Dermatology.
Researchers conducted a study using clinical photographs of 11 patients with melanoma-associated leukoderma (MAL) and 33 patients with vitiligo at The Netherlands Institute for Pigment Disorders in Amsterdam. Read more